Urology Center of Englewood
Latest Clinical News

FDA Approves Xtandi for Treatment of Castration-resistant Prostate Cancer (07-17-2018)

On July 13, 2018, the Food and Drug Administration approved Xtandi (enzalutamide) for patients with castration-resistant prostate cancer (CRPC).  This approval broadens the indicated patient population to include patients with both non-metastatic CRPC... Continue Reading

Vicinium Represents New Treatment Option for Non- Muscle Invasive Badder Cancer (06-6-2018)

Today three-month data from the ongoing Phase 3 VISTA Trial of Vicinium for the treatment of patients with high-grade non-muscle invasive bladder cancer (NMIBC) who have been previously treated with bacillus Calmette-Guérin (BCG) were released. Overall... Continue Reading

U.S. FDA Grants Fast Track Designation to GemRIS™ in Muscle Invasive Bladder Cancer (05-4-2018)

CancerConnect News: The United States Food and Drug Administration (FDA) has granted Fast Track designation for GemRIS (TAR-200) for the treatment of patients with organ-confined or locally-advanced Muscle Invasive Bladder Cancer who are unfit for curative... Continue Reading

Immediate vs Delayed Androgen Deprivation Therapy in Prostate Cancer (05-1-2018)

CancerConnect News: There is an ongoing discussion about the optimal timing of using androgen deprivation therapy (ADT) in men with prostate cancer who have relapsed based on a rising prostate-specific antigen (PSA) and in men with early stage prostate... Continue Reading

Breakthrough Therapy Designation Awarded for Enfortumab Vedotin in Locally Advanced or Metastatic Bladder Cancer (04-3-2018)

CancerConnect News: The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to enfortumab vedotin for patients with locally advanced or metastatic urothelial (bladder) cancer who were previously treated with checkpoint... Continue Reading

Keytruda Improves Survival of Advanced Bladder Cancer (02-26-2018)

CancerConnect News: Patients with recurrent urothelial cancer lived longer when they received Keytruda (pembrolizumab) compared to chemotherapy as second-line treatment, according to long-term follow of a clinical trial presented at the Genitourinary... Continue Reading

Xtandi® A New Standard Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer? (02-22-2018)

CancerConnect News:  Results from the Phase 3 PROSPER clinical trial in patients with non-metastatic Castration-Resistant Prostate Cancer (CRPC) were released this week at the 2018 Genitourinary Cancers Symposium in San Francisco and demonstrate that... Continue Reading

Erleada is The First Treatment for Non-metastatic Castration-resistant Prostate Cancer (02-19-2018)

CancerConnect News:  Men who are being treated with androgen deprivation therapy (ADT) and see their prostate specific antigen (PSA) levels begin to increase have a new treatment option. The U.S. Food and Drug Administration (FDA) has approved Erleada... Continue Reading

Myriad’s myRisk® Hereditary Cancer Test Finds More Than 12 Percent of Men with Prostate Cancer Carry an Inherited Genetic Mutation (02-14-2018)

Myriad Genetics a leader in molecular diagnostics and personalized medicine, announced today that results from a large 1,162 patient study will be featured during the poster presentation at the 2018 Genitourinary Cancer Symposium in San Francisco, Calif. ... Continue Reading

Two Advances in Prostate Cancers You Might Not Know About (09-8-2017)

Prostate cancer isn’t just about men, and it may be inherited. A recent study led by Peter Nelson, MD (Fred Hutchinson Cancer Research Center) has shown that 12% of advanced prostate cancers may be caused by 16 different heritable genes. That means... Continue Reading

Is Lynparza a Precision Cancer Medicine for Prostate Cancer? (07-12-2017)

Scientists have developed a new three-in-one blood test that has the potential to turn Lynparza (olaparib) into a precision medicine for prostate cancer. Lynparza is a PARP inhibitor, a newer precision cancer medicine that blocks enzymes involved in repairing... Continue Reading

Abiraterone Delays Metastatic Prostate Cancer Growth by 18 Months, Extends Survival (06-7-2017)

Adding Zytiga (abiraterone acetate) plus prednisone to standard hormonal therapy for men with newly diagnosed, metastatic prostate cancer lowers the chance of death by 38%, and more than doubled the median time until the cancer worsened, from 14.8 months... Continue Reading

Next Page »